Inhalation Sciences receives IRS order worth 118,464 Euro from US client following 50,000 Euro deposit
(Stockholm, Sweden, 7 March 2023) On 7 February 2023 Inhalations Sciences AB (ISAB) announced that a returning US client had paid a 50,000 Euro deposit to book lab time and facilities in April 2023 for an Inhalation Research Services’ R&D project. The client has now confirmed the entire IRS order, totaling 118,484 Euro (approx. 1.3 MSEK), of which 50,000 Euro has already been paid.
A returning ISAB client, a mid-size US pharma company, has confirmed an IRS order worth 118,484 Euros in total following an advanced payment in February of 50,000 Euro.
The client has chosen ISAB’s high-precision IPL (Isolated Perfused Lung) method to carry out the IRS project. IPL is a well-established experimental model in preclinical pharma studies for both biologics and small molecules, ISAB’s version however is specially tailored and designed for aerosols generated by the company’s precision dosing aerosol system PreciseInhale®.
ISAB CEO Manoush Masarrat: “This new order reconfirms how successful our new strategic focus on Inhalation Research Services (IRS) is. Small to Medium-sized Enterprises developing inhaled drugs have an unmet need. They are looking for service providers who can deliver high-precision preclinical data that can de-risk their work from day one. We can meet that need. We look forward to starting work again with this returning US client”.
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and Dissolv It® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 7 March 2023.
Tags: